$传奇生物(LEGN)$ Legend Biotech：Carvykti 的崛起
传奇生物科技公司（纳斯达克股票代码：LEGN）因其用于成人骨髓癌治疗的 Carvykti 药物的提振而成为另一个首选。 Piper Sandler 将其描述为“同类最佳”，需求超过供应。
该投资银行预测收入将从 2023 年的 5.06 亿美元大幅飙升至 2024 年的 10.5 亿美元，预计到 2025 年全球供应量将达到每年 10,000 剂，可能将峰值收入推至 50 亿美元以上。
Piper Sandler 对传奇生物强大的 CAR-T 细胞治疗产品线以及最近与诺华的合作做出了贡献，他预计明年股价将增长 53.3%。Legend Biotech: Carvykti's Rise to Prominence$金斯瑞生物科技(01548)$
Legend Biotech Corp (NASDAQ:LEGN) emerges as another top pick, buoyed by its Carvykti drug for adult bone marrow cancer treatment. Piper Sandler describes it as "best in class," with demand surpassing supply.Predicting a substantial revenue surge from $506 million in 2023 to $1.05 billion in 2024, the investment bank foresees global supply reaching 10,000 doses annually by 2025, potentially pushing peak revenue beyond $5 billion.
Legend Biotech's robust CAR-T Cell therapy pipeline and recent collaboration with Novartis contribute to Piper Sandler's bullish outlook, expecting a 53.3% increase in shares over the next year.